We then demonstrated that pharmaceutical inhibition of KC binding with reparixin (Figure 6B), a CXCR2 antagonist that has been used in trials for the treatment of breast cancer [25], ameliorated PM-induced increased severity of pulmonary fibrosis. Here, CXCR2 is linked to breast carcinoma.